 CAMBRIDGE, Mass., Sept. 26, 2022 GLOBE NEWSWIRE -- TCR2 Therapeutics Inc. Nasdaq: TCRR, a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the Jefferies Cell Genetic Medicine Summit on Thursday, September 29 at 2:00PM E.T. 